DeuterOncology is a preclinical-stage biotechnology company dedicated to developing innovative cancer therapies. The company's primary focus is on a first-in-class dual MET and RAS pathway inhibitor, currently under investigation as a targeted treatment for lung cancer. This lead compound aims to enhance oncology treatment outcomes and may have broader applications when combined with standard of care and other targeted agents. By optimizing the therapeutic approach to cancer, DeuterOncology seeks to improve the effectiveness of treatment options available to medical professionals and ultimately benefit cancer patients.
EditForce is a biotechnology company based in Fukuoka, Japan, founded in 2015. The company specializes in nucleic acid manipulation technologies, focusing on genome editing and transcriptome editing. Utilizing pentatricopeptide repeat (PPR) protein engineering, EditForce develops tools for precise editing of DNA and RNA sequences. Their technology is applicable in various fields, including agriculture, pharmacy, and biological research, facilitating advancements in drug development and seed research. By offering an alternative option to traditional genome editing methods, EditForce aims to enhance the capabilities of researchers and contribute to innovations in medicine and bio-production.
DeuterOncology is a preclinical-stage biotechnology company dedicated to developing innovative cancer therapies. The company's primary focus is on a first-in-class dual MET and RAS pathway inhibitor, currently under investigation as a targeted treatment for lung cancer. This lead compound aims to enhance oncology treatment outcomes and may have broader applications when combined with standard of care and other targeted agents. By optimizing the therapeutic approach to cancer, DeuterOncology seeks to improve the effectiveness of treatment options available to medical professionals and ultimately benefit cancer patients.
Perseus Proteomics Inc. operates as a drug discovery bio-venture company in Japan. It is involved in the antibody discovery, antibody engineering, target discovery, and functional protein expression business; and antibody research support activities comprising mouse hybridoma sequencing, recombinant protein production, and contract antibody research activities, as well as development, manufacture, and supply of antibody products. The company was founded in 2001 and is headquartered in Tokyo, Japan.
AbolerIS Pharma operates as a biotech company that engages in the development of immune-modulators for the treatment of transplant rejection, graft-versus-host-disease, and auto-immune diseases. The company’s products include Anti-CD45RC, a monoclonal antibody that deplete effector T cells; and IL-34, cytokine to induce tolerogenic macrophages and regulatory T cells. AbolerIS Pharma was incorporated in 2019 and is based in Nantes, France.
J-Pharma Co., Ltd. develops therapeutics and diagnostic agents for treatment of cancer. The company was founded in 2005 and is based in Yokohama, Japan.
EditForce is a biotechnology company based in Fukuoka, Japan, founded in 2015. The company specializes in nucleic acid manipulation technologies, focusing on genome editing and transcriptome editing. Utilizing pentatricopeptide repeat (PPR) protein engineering, EditForce develops tools for precise editing of DNA and RNA sequences. Their technology is applicable in various fields, including agriculture, pharmacy, and biological research, facilitating advancements in drug development and seed research. By offering an alternative option to traditional genome editing methods, EditForce aims to enhance the capabilities of researchers and contribute to innovations in medicine and bio-production.
Acticor Biotech SAS is a biotechnology company based in Paris, France, focused on developing therapeutic monoclonal antibodies for acute thrombotic diseases, particularly ischemic stroke. The company's lead product, Glenzocimab, is a humanized antibody aimed at addressing the critical need for new treatment options in the acute phase of stroke. Stroke affects approximately 15 million people worldwide each year, resulting in significant mortality and disability. Current treatment options are limited, with only one recommended therapy that benefits a small percentage of patients, highlighting the urgent demand for more effective solutions. Acticor Biotech was founded in 2013 and aims to provide innovative therapies that can significantly improve outcomes for stroke patients.
Acticor Biotech SAS is a biotechnology company based in Paris, France, focused on developing therapeutic monoclonal antibodies for acute thrombotic diseases, particularly ischemic stroke. The company's lead product, Glenzocimab, is a humanized antibody aimed at addressing the critical need for new treatment options in the acute phase of stroke. Stroke affects approximately 15 million people worldwide each year, resulting in significant mortality and disability. Current treatment options are limited, with only one recommended therapy that benefits a small percentage of patients, highlighting the urgent demand for more effective solutions. Acticor Biotech was founded in 2013 and aims to provide innovative therapies that can significantly improve outcomes for stroke patients.
Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.
ChromaCure will launch a drug development program to identify potential new candidates that selectively and potently inhibit cancer targets and potentially provide novel therapy for multiple forms of cancer, either as monotherapy or in combination with immunotherapy or chemotherapy.
Synergia Medical aims at developing and commercializing next generation neurostimulation devices. It relies on a seasoned management team with extensive experience in developing implantable neurostimulators.
In only three years time, the company became ISO13485 certified, created and sold an OEM external neurostimulator for a motorized amputee prosthesis arm and developed its first version of the NAOS platform.
Supported by private investors and public research grants, the company has quickly grown to a team of thirteen highly skilled multidisciplinary professionals.
DIM3 SA develops and markets clinical expert platforms and medical devices for clinical nutrition management. Its products include Scorso, an application for the screening and follow up of disease related malnutrition; Nutrow, a decision support software for an optimization of clinical nutrition; and Biocorder, a clinical mobile assistant medical box. The company was founded in 2013 and is headquartered in Beaufays, Belgium.